Literature DB >> 17541852

Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.

Alexandra Zourková1, Eva Cesková, Eva Hadasová, Barbara Ravcuková.   

Abstract

The aim of the study was to compare the distribution of therapeutic efficacy and sexual dysfunction during maintenance paroxetine treatment in 17 males and 38 females genotyped and phenotyped to determine their CYP2D6 metabolic status. Clinical results were monitored on scales Clinical Global Impression-Severity of Illness Scale (CGIS) and Arizona Sexual Experience Scale (ASEX). The phenotype procedure showed 7 males and 12 females with extensive metabolic status (EM) and 10 males and 26 females with poor metabolic status (PM). No variation in therapeutic efficacy between male and female subjects classified as PM and those marked as EM was found. A significantly higher rate of sexual dysfunction (p = 0.01) was recorded among females with a PM phenotype.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17541852     DOI： 10.1080/00926230701385589

Source DB:  PubMed          Journal:  J Sex Marital Ther        ISSN： 0092-623X


  10 in total

1.  Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.

Authors:  Alice I Nichols; Kristen Focht; Qin Jiang; Sheldon H Preskorn; Cecelia P Kane
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

Review 3.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 4.  Impact of Antidepressant Drugs on Sexual Function and Satisfaction.

Authors:  David S Baldwin; Chris Manson; Magda Nowak
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

5.  The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.

Authors:  Angel L Montejo; Laura Montejo; David S Baldwin
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

6.  P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects.

Authors:  Michael J Bly; Jeffrey R Bishop; Kelan L H Thomas; Vicki L Ellingrod
Journal:  J Sex Marital Ther       Date:  2013-01-28

7.  Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants.

Authors:  David S Baldwin; M Carlotta Palazzo; Vasilios G Masdrakis
Journal:  Depress Res Treat       Date:  2013-02-04

Review 8.  Delayed Ejaculation: Pathophysiology, Diagnosis, and Treatment.

Authors:  Ibrahim A Abdel-Hamid; Omar I Ali
Journal:  World J Mens Health       Date:  2018-01       Impact factor: 5.400

9.  Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Authors:  T L Lash; L Pedersen; D Cronin-Fenton; T P Ahern; C L Rosenberg; K L Lunetta; R A Silliman; S Hamilton-Dutoit; J P Garne; M Ewertz; H T Sørensen
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

10.  CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression.

Authors:  Kyu-Man Han; Hun Soo Chang; In-Kwang Choi; Byung-Joo Ham; Min-Soo Lee
Journal:  Psychiatry Investig       Date:  2013-09-16       Impact factor: 2.505
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.